Seeking to Expand Collaboration in New Drug Development, Open Innovation, and Product Portfolio
On June 10, Celltrion announced that it will participate in the "2025 Bio International Convention" (Bio International Convention·Bio USA), which will be held in Boston, United States, for four days from June 16 (local time) to June 19. The company aims to strengthen its global partnerships through this event.
Now in its 32nd year, Bio USA is the world’s largest bio exhibition event, with more than 1,800 pharmaceutical and biotech companies from around the globe participating. Celltrion has participated in Bio USA for 16 consecutive years since 2010, promoting its technological competitiveness and brand in core areas such as biosimilars and new drug development, while continuously expanding partnerships within the related industries.
At this year’s event, Celltrion will operate an independent booth of approximately 140 square meters, providing both open meeting spaces and private meeting rooms to facilitate meetings with numerous global companies. Through this, the company plans to identify promising trends in new modality development and seek collaborations with potential partners, with the goal of expanding its new drug pipeline, including next-generation antibody-drug conjugates (ADCs) and novel antibody drugs.
In fact, aiming to become a global new drug development company, Celltrion began to accelerate its new drug development this March after receiving FDA approval for a Phase 1 IND (Investigational New Drug) application for its next-generation ADC candidate "CT-P70". In addition, the company plans to sequentially submit IND applications for follow-up multi-antibody and ADC new drugs, including "CT-P71" and "CT-P72", within this year, and to develop a total of 13 new drug candidates in the ADC and multi-antibody fields by 2028, thereby expanding its new drug pipeline.
Furthermore, at Bio USA, Celltrion plans to promote the competitiveness of its biosimilar products and follow-up pipeline to event participants, while also strengthening partnerships in various fields such as global bio cluster networks and contract manufacturing organization (CMO) site collaborations. Having achieved its goal of establishing a portfolio of 11 biosimilars ahead of schedule last year, Celltrion plans to further diversify its portfolio in the second half of this year by launching four high-profit new biosimilars (Omriclo, Idenzelt, Aptosma, Stoboclo & Ocenbelt) in major global markets.
In particular, this year, Celltrion will participate in the "Company Presentation" session at Bio USA to showcase its unique business capabilities, covering the entire process from drug research and development, clinical trials, approval, production, to sales, to industry stakeholders. The company also plans to broadly introduce its open innovation strategies for new drug development and the discovery of promising technologies. Through these efforts, Celltrion aims to identify capable potential partners that align with its new drug development direction and expand its global sourcing channels.
A Celltrion official stated, "Based on our proven competitiveness in the global biosimilar market, this year we will accelerate efforts to promote Celltrion’s new business segment as a company advancing into new drug development, and actively seek out various promising technologies to expand our new drug pipeline. At this year’s Bio USA, we aim to further strengthen global partnerships by identifying potential partners with innovative technologies and expanding open innovation."
Meanwhile, Celltrion also plans to participate in "CPHI (Convention on Pharmaceutical Ingredients) Worldwide 2025," one of the world’s largest pharmaceutical exhibitions, to be held in Frankfurt, Germany, in the second half of this year, continuing its global partnership activities to enhance its corporate brand competitiveness.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
